VANDA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.36 USD | -2.19% |
|
+12.37% | +27.01% |
| May. 08 | Transcript : Vanda Pharmaceuticals Inc., Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $47.5M | MT |
Presenter SpeechOlivia Brayer (Analysts)All right. Good morning, everyone, and welcome to our ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâs commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Calendar
2024-05-17
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
5.36
USD
Average target price
5.21
USD
Spread / Average Target
-2.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.01% | 312M | |
| +2.93% | 108B | |
| +7.02% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- VNDA Stock
- News Vanda Pharmaceuticals Inc.
- Transcript : Vanda Pharmaceuticals Inc. Presents at BofA Securities 2021 Virtual Health Care Conference, May-13-2021 11